Latest research on Nevirapine

A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. [PubChem] Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.

Latest findings

The majority (92%) of NNRTI users initiated cART with Efavirenz, with the remaining receiving Nevirapine (5%) or rilpivirine (3%). [source, 2016]
Several studies including HIV-HCV–coinfected persons have shown an association between hepatotoxicity, fibrosis, or clinical liver outcomes and Nevirapine use, but not Efavirenz [6, 26–28], which represented 92% of NNRTI use in this cohort. [source, 2016]
There has been a gradual shift of patients from older combinations (e.g. those including Stavudine, Didanosine, Zidovudine or Nevirapine) onto this single-tablet regimen. [source, 2016]
The complexity and cost of first-line PI-based treatment remains significantly higher than the use of EFV or Nevirapine. [source, 2016]
The efficacy of EFV-based treatment is similar for people either taking or not taking rifampicin-based treatment (in contrast to Nevirapine, which shows lower efficacy when co-administered with rifampicin) [20]. [source, 2016]
All the patients included in the study initiated ART with reverse transcriptase inhibitor (RTI) drugs, that is, two nucleoside reverse transcriptase inhibitors (NRTI), Zidovudine (AZT) or Stavudine (d4T) with Lamivudine (3TC) + one non-nucleoside reverse transcriptase inhibitor (NNRTI), either Nevirapine (NVP) or Efavirenz (EFV) as per the standard national AIDS programme guidelines.24 [source, 2016]
Clinical studies which have observed a pharmacokinetic–pharmacodynamic relationship (e.g. Efavirenz [11], Nevirapine [12], Lopinavir [13], raltegravir [14]) have defined antiretroviral minimum effective concentrations (MEC). [source, 2016]
Where tail studies have not been undertaken (e.g. Nevirapine, etravirine, raltegravir, maraviroc), an estimate of regimen forgiveness can be extrapolated using average drug half-lives from standard pharmacokinetic studies, though this is likely to be less accurate. [source, 2016]
Tail data are not available for maraviroc, raltegravir, Nevirapine or etravirine. [source, 2016]
Significant symptoms from overdose of Nevirapine have only been reported at 800 mg or above [27]. [source, 2016]